Merck Reports the Results of V116 in P-III trial (STRIDE-3) for the treatment of Pneumococcal Infection in Adults
Shots:
- The P-III trial (STRIDE-3) evaluating immunogenicity, tolerability & safety Of V116 vs PCV20 in 2 cohorts; aged 50+ & 18 to 49 in 1:1 & 2:1 ratio respectively on adults (n=2663) who had not previously received a pneumococcal vaccine
- In cohort 1, V116 demonstrated non-inferior immune responses to PCV20 for 10 serotypes common in both & superior responses for 10 of 11 additional serotypes (included in V116 but not in PCV20), as measured by OPA at Day 30. In cohort 2, V116 showed non-inferior immune responses vs cohort 1. Additionally, V116 exhibited a safety profile comparable to PCV20 across both cohorts
- V116, is a 21-valent pneumococcal conjugate vaccine tailored to target Streptococcus pneumoniae serotypes that play a major role in adult pneumococcal disease
Ref: Merck | Image: Merck
Related News:- Merck to Acquire Caraway Therapeutics for ~$610M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
